The schizophrenia drug field has its problems, says SA author Tiran Rothman. The treatments are...
The schizophrenia drug field has its problems, says SA author Tiran Rothman. The treatments are inadequate, with under 50% of patients responding well to them and 20% not responding at all. That, plus a patent cliff presents an opportunity for firms developing the next generation of medicines. These include Lundbeck (HLUKF.PK), Targacept (TRGT), Bioline Rx (BLRX) and Addex Therapeutics (ADDXF.PK).
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs